Poster-Quality of Life and Outcomes
October 25, 2021
Characterizing Activities of Daily Living in MS Patients with Processing Speed Scores Above and below a Threshold Previously Shown to Predict Employment Status
Background: Cognitive impairment can occur early in the course of multiple sclerosis (MS) and worsen progressively over time, impacting...
October 25, 2021
The Effect of Hypnotics and Stimulants on Fatigue, Sleep, and Quality of Life Outcomes in a Multiple Sclerosis Cohort
Background: Sleep disturbance in persons with multiple sclerosis (pwMS) is associated with fatigue, depression, future cognitive decline,...
Poster-Quality of Life and Outcomes
October 25, 2021
Patient-Reported Outcome Measures in Multiple Sclerosis Clinical Trials: Critical Assessment and Insights from People Living with Multiple Sclerosis
Background: Multiple sclerosis (MS) clinical trials often include patient-reported outcomes (PROs) to quantify treatment effects not...
Poster-Quality of Life and Outcomes
October 25, 2021
Improving Communication about Multiple Sclerosis: The MS-Support Decision Aid
Background: Good communication between patients and their health care provider (HCP) is essential for shared decision making (SDM). We...
Poster-Disease-modifying Therapy
October 25, 2021
Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis
INTRODUCTION Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of relapsing forms of multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder
Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Eculizumab in Nmosd and MG Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions
Background: Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem
Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefitrisk profile in patients with relapsing-remitting...
Poster-Disease-modifying Therapy
October 25, 2021
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent
Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...
Poster-Disease-modifying Therapy
October 25, 2021
Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study
Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...